Table 4. Nonrelapse deaths . Haplo (n =... | American Society of Hematology

Table 4.

Nonrelapse deaths

	Haplo (n = 170)		Haplo-cord (n = 137)
	n (%)	Cumulative Incidence at 1 y, % (95% CI)	n (%)	Cumulative incidence at 1 y, % (95% CI)	P (Gray test)
Fatal infection	13 (7)	7.6 (7.4-8)	20 (15)	6.6 (6.2-7.0)	.51
GVHD	9 (5)	3.5 (3.2-3.8)	1 (1)	0.0 (0-0.01)	.02
Acute GVHD	7 (4)	2.3 (2.1-2.5)	1 (1)	0.0 (0-0.01)	.06
Chronic GVHD	2 (1)	1 (0.8-1.2)	0	0	.20
PTLD	0	0	4 (3)	2.9 (2.6-3.2)	.01
Graft rejection/poor graft function	3 (1.5)	1.8 (1.6-2)	8 (6)	5 (4.6-5.4)	.06
Unknown	5 (3)		0
Other	9 (5)*		5 (3.5)†

	Haplo (n = 170)		Haplo-cord (n = 137)
	n (%)	Cumulative Incidence at 1 y, % (95% CI)	n (%)	Cumulative incidence at 1 y, % (95% CI)	P (Gray test)
Fatal infection	13 (7)	7.6 (7.4-8)	20 (15)	6.6 (6.2-7.0)	.51
GVHD	9 (5)	3.5 (3.2-3.8)	1 (1)	0.0 (0-0.01)	.02
Acute GVHD	7 (4)	2.3 (2.1-2.5)	1 (1)	0.0 (0-0.01)	.06
Chronic GVHD	2 (1)	1 (0.8-1.2)	0	0	.20
PTLD	0	0	4 (3)	2.9 (2.6-3.2)	.01
Graft rejection/poor graft function	3 (1.5)	1.8 (1.6-2)	8 (6)	5 (4.6-5.4)	.06
Unknown	5 (3)		0
Other	9 (5)*		5 (3.5)†

Haplo: hemorrhage, 3; secondary malignancy, 1; liver failure/veno-occlusive disease, 1; adult respiratory distress syndrome/respiratory failure, 2; cardiac failure, 2.

†

Haplo-cord: liver failure/VOD, 1; ARDS/respiratory failure, 3; vasculitis, 1.

View Large

This Feature Is Available To Subscribers Only